Nasus Pharma (NSRX) is advancing a statistically superior, needle-free intranasal epinephrine powder toward a pivotal Q4 2026 study, backed by Phase 2 data that beat the EpiPen’s speed-to-thr
ORLANDO, FL / ACCESS Newswire / April 21, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays...
ORLANDO, FL / ACCESS Newswire / April 7, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual...
WSW, NY, 24th November 2025, FinanceWire … Read More
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...